Results showed that TRIM28 expression was positively correlated with TMB in multiple cancer types, indicating that TRIM28 might be a robust biomarker for initiating immunotherapy in multiple cancers (Supplementary Fig. S7a). The gene discussed is TRIM28; the disease is cancer.